Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Pharma
In a first, Otsuka’s Voyxact stabilizes IgAN kidney loss in ph.3
The first-in-class drug achieved an annualized eGFR slope of a +0.3 mL/min/1.73m² over two years, matching normal levels seen in healthy adults.
Angus Liu
Aug 3, 2026 5:00pm
Supernus-Indivior merger is about scale, business development
Aug 3, 2026 11:20am
Inside Noble’s connected approach to patient support
Brought to you by
NOBLE, Inc
Amgen says patient data, IP stolen in cybersecurity breach
Aug 3, 2026 11:05am
What Hub Transitions Really Cost Manufacturers
Brought to you by
Gifthealth
Sandoz inks dual settlements to resolve most US antitrust claims
Aug 3, 2026 10:18am
